Sanofi (SNY) issued the following statement regarding Horizon Therapeutics plc (HZNP): "Sanofi S.A. regularly evaluates a wide variety of business development opportunities and this has included the evaluation of a possible transaction involving Horizon. As transaction price expectations do not meet our value creation criteria, Sanofi announces it is no longer in discussions with Horizon and it does not intend to make an offer for Horizon. This announcement is intended to be treated as a statement to which Rule 2.8 of the Takeover Rules applies."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HZNP:
- Amgen (NASDAQ:AMGN) to Buy Horizon for $27.8B; HZNP Stock Rallies
- Horizon Therapeutics announces first subject does in HZN-457 trial
- Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
- J&J says ‘it does not intent to make offer’ for Horizon Therapeutics
- J&J says won’t make offer for Horizon Therapeutics, Bloomberg reports